A case is reported in which tubocurarine crossed the placental barrier and paralyzed a 28-week foetus. The mother was under treatment for status epilepticus. The authors review the present evidence for the transplacental passage of tubocurarine and suggest that previous work may not represent the situation accurately. Reference is made to a further case which also suggests transplacental passage of tubocurarine, this time in the first trimester of pregnancy. Curare was first introduced into anaesthesia by Griffith and Johnson in 1942. As far as the writers are aware, there have been no reports of foetal depression from the use of tubocurarine in obstetrics. Following the work of Gray (1947), Whitacre and Fisher (1948), Pittinger, Morris and Keettel (1953), Cohen and associates (1953) and Crawford and Gardiner (1956), it has been accepted that the drug does not cross the placental barrier in sufficient quantities to cause paralysis of the foetus. Moya and Smith (1965), in thensurvey of the placental transport of drugs, point out that the placental barrier is relative rather than absolute. The authors feel that this is all too often forgotten, particularly so with the increase in the use of large and repeated doses of muscle relaxants and controlled pulmonary ventilation in the management of many disease conditions.